PetMed Express - PETS Stock Forecast, Price & News

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for PetMed Express in the last year. There are currently 1 sell rating for the stock. The consensus among Wall Street equities research analysts is that investors should "sell" PETS shares.
View PETS analyst ratings or view top-rated stocks.

1 analysts have issued 12 month price targets for PetMed Express' shares. Their PETS share price forecasts range from $18.00 to $18.00. On average, they expect the company's stock price to reach $18.00 in the next twelve months. This suggests a possible upside of 9.7% from the stock's current price.
View analysts price targets for PETS or view top-rated stocks among Wall Street analysts.

PetMed Express' stock was trading at $17.70 at the beginning of 2023. Since then, PETS stock has decreased by 7.3% and is now trading at $16.41.
View the best growth stocks for 2023 here.

PetMed Express saw a decrease in short interest during the month of February. As of February 28th, there was short interest totaling 4,200,000 shares, a decrease of 13.2% from the February 13th total of 4,840,000 shares. Based on an average daily trading volume, of 380,300 shares, the days-to-cover ratio is currently 11.0 days.
View PetMed Express' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Monday, May 8th 2023.
View our PETS earnings forecast.

PetMed Express, Inc. (NASDAQ:PETS) announced its earnings results on Sunday, October, 24th. The company reported $0.31 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.34 by $0.03. The firm earned $67.39 million during the quarter, compared to analysts' expectations of $70.90 million. PetMed Express had a trailing twelve-month return on equity of 8.54% and a net margin of 4.38%. During the same quarter in the previous year, the firm posted $0.42 EPS.

PetMed Express announced a quarterly dividend on Monday, February 6th. Investors of record on Monday, February 20th will be paid a dividend of $0.30 per share on Monday, February 27th. This represents a $1.20 dividend on an annualized basis and a dividend yield of 7.31%. The ex-dividend date of this dividend is Thursday, February 16th.
Read our dividend analysis for PETS.

ETFs with the largest weight of PetMed Express (NASDAQ:PETS) stock in their portfolio include Formidable ETF (FORH), Invesco S&P SmallCap High Dividend Low Volatility ETF (XSHD), Amplify Online Retail ETF (IBUY), Global SuperDividend US ETF (DIV), SPDR S&P Internet ETF (XWEB), ProShares Russell 2000 Dividend Growers ETF (SMDV), Roundhill Acquirers Deep Value ETF (DEEP) and RiverFront Dynamic US Dividend Advantage ETF (RFDA).

PetMed Express (NASDAQ:PETS) pays an annual dividend of $1.20 per share and currently has a dividend yield of 6.93%. PETS has a dividend yield higher than 75% of all dividend-paying stocks, making it a leading dividend payer. The dividend payout ratio is 210.53%. Payout ratios above 75% are not desirable because they may not be sustainable. Based on EPS estimates, PETS will have a dividend payout ratio of 160.00% in the coming year. This indicates that the company may not be able to sustain their current dividend.
Read our dividend analysis for PETS.

5 employees have rated PetMed Express Chief Executive Officer Mendo Akdag on Glassdoor.com. Mendo Akdag has an approval rating of 46% among the company's employees. This puts Mendo Akdag in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other PetMed Express investors own include Intel (INTC), NVIDIA (NVDA), AT&T (T), Cisco Systems (CSCO), Alibaba Group (BABA), Gilead Sciences (GILD), Advanced Micro Devices (AMD), Verizon Communications (VZ), Netflix (NFLX) and Micron Technology (MU).

PetMed Express trades on the NASDAQ under the ticker symbol "PETS."

PetMed Express' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Renaissance Technologies LLC (4.43%), Charles Schwab Investment Management Inc. (2.96%), ProShare Advisors LLC (2.83%), Mirae Asset Global Investments Co. Ltd. (2.80%), Dimensional Fund Advisors LP (2.77%) and Geode Capital Management LLC (2.05%). Insiders that own company stock include Bruce S Rosenbloom, Gian Fulgoni, Menderes Akdag and Ronald J Korn.
View institutional ownership trends.

Shares of PETS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of PETS stock can currently be purchased for approximately $16.41.

PetMed Express (NASDAQ:PETS) has a market capitalization of $345.92 million and generates $273.42 million in revenue each year. The company earns $21.10 million in net income (profit) each year or $0.57 on an earnings per share basis.

The company employs 219 workers across the globe.

PetMed Express' mailing address is 420 SOUTH CONGRESS AVENUE, DELRAY BEACH FL, 33445. The official website for the company is www.1800petmeds.com. The company can be reached via phone at (561) 526-4444, via email at investor@petmeds.com, or via fax at 561-526-4445.